Drugs /

membrane-bound interleukin-21-expanded haploidentical natural killer cells

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of human cytokine interleukin-21 (IL-21) primed, tumor-activated allogeneic human leukocyte antigen (HLA) haploidentical natural killer (NK) cells, with potential cytolytic and immunoregulatory activities. Allogeneic leukemia cells are genetically modified to express membrane-bound interleukin-21 (mbIL-21) on their cell surfaces. When human peripheral blood mononuclear cells (PBMCs) from an HLA-haploidentical donor are subsequently exposed to these cells, the donor PBMC differentiate into mature, highly cytotoxic NK cells, which are subsequently expanded in ex vivo culture. Upon infusion of the mbIL-21-expanded haploidentical NK cells, the NK cells target, lyse and destroy tumor cells. mbIL-21 promotes sustained ex vivo proliferation of human NK cells and enhances its cytotoxic activity.

Clinical Trials

View Clinical Trials for membrane-bound interleukin-21-expanded haploidentical natural killer cells

Membrane-bound interleukin-21-expanded haploidentical natural killer cells has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating membrane-bound interleukin-21-expanded haploidentical natural killer cells, 1 is phase 1 (1 open).

TET2 Loss, TET2 Mutation, and TP53 Loss are the most frequent biomarker inclusion criteria for membrane-bound interleukin-21-expanded haploidentical natural killer cells clinical trials.

Acute myeloid leukemia and myelodysplastic syndromes are the most common diseases being investigated in membrane-bound interleukin-21-expanded haploidentical natural killer cells clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Membrane-Bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating membrane-bound interleukin-21-expanded haploidentical natural killer cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
(mbil21)-expanded haploidentical nk cells, mbil21-expanded haploidentical nk cells
NCIT ID [1]:
C131901

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.